SAN DIEGO, Dec. 15, 2015 /PRNewswire/ -- HUYA Bioscience International (HUYA) today announced the appointment of Scott Garrett, M.B.A. as Vice President, Commercial Planning. His addition to the senior management team will support the Company's advancement of its lead anti-cancer drug HBI-8000 as well as the development of HUYA's pipeline of cardiovascular products.
Scott has over 20 years of commercial experience in both drugs and devices for oncology and cardiovascular disease with companies such as Celladon, Mallinckrodt, Gilead, Johnson and Johnson, Boston Scientific and Nycomed Amersham (now GE Healthcare). His prior responsibilities include sales and marketing, commercial planning, product launch, healthcare economics, reimbursement, advocacy development, life cycle management, and business development for brands such as CERETEC®, TAXUS®, NATRECOR®, RANEXA® and OFIRMEV®.
"Scott's commercial experience in oncology and cardiovascular disease will play a key role as HUYA transitions from a development to a commercial-stage company," said Mireille Gillings Ph.D., CEO of HUYA. "We welcome him to the HUYA Senior Management team, where he will assume responsibility for the Company's increasing commercial focus."
Scott received his M.B.A from the University of California, Irvine and a B.S from San Diego State. He holds several marketing and advertising awards.
About HUYA Bioscience International
HUYA is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. HUYA was awarded the Asia-Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category and a Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit www.huyabio.com
HUYA Corporate Communications
+1 858 353 1217
SOURCE HUYA Bioscience International